Is a negative prostate biopsy a risk factor for a prostate cancer related death? by Emberton, M
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‘Good news, Mr. Jones – your prostate biopsy is clear – your risk of dying of 
prostate cancer is now twice the average’. 
 
Mark Emberton FMedSci 
Professor of Interventional Oncology, UCL Division of Surgery and Interventional 
Science, London WC1E 6BT  
 
About 30 years ago, Tom Stamey persuaded urologists to abandon a diagnostic 
approach to prostate cancer that was predicated on measurable disease to one that 
was not (1).  The new and ‘better’ approach was a semi-random interrogation of the 
prostate – otherwise known as the trans-rectal biopsy, most often triggered by an 
elevated PSA.  Urologists have never been entirely comfortable with PSA-Biopsy as a 
risk-stratification tool.  The number of needle deployments has increased with time 
in order to overcome the sampling error.  The poor criterion validity of PSA-Biopsy 
has been very evident to surgeons who witness ‘upgrading’ in up to half of the 
patients they operate on compared to the risk that was predicted on PSA-Biopsy (2).  
 
Assessing the true utility of PSA-Biopsy has proved challenging but we now have 
studies that span the PSA-Biopsy era. The SPCG-4 study recruited men before PSA 
was available (3); PIVOT was right in the middle with exactly half the patients 
presenting with T1c disease (4); ProtecT was the near perfect application of PSA-
Biopsy at a community level (5).  Prostate cancer mortality in the men randomized to 
conservative care within these studies was 20%, 8% and 1%, respectively. In other 
words, the better PSA-Biopsy was applied the worse it performed at identifying men 
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at risk.  PROMIS – one of the first studies to assess the diagnostic accuracy of TRUS-
Biopsy against an exacting reference standard – has shown what many have long felt 
(6). TRUS-Biopsy missed over half of all clinically significant prostate cancers.  So, it is 
possible that we have been telling just over half the men with clinically significant 
prostate cancer that they are either ‘all clear’ or have insignificant disease.  
 
So what happens to the men who are exposed to TRUS-Biopsy and are given the ‘all 
clear’ by their doctors? The paper by Klemann and colleagues in this issue provides 
some insight (7). In summary, they tracked the fate (in April 2015) of 64,430 men 
who were referred for TRUS-guided biopsy during the period spanning 1995-2011. 
Just over 27,000 of these men tested negative on their initial exposure to the biopsy. 
Despite a relatively short median follow-up (5.9 years), the authors reported a 1 in 
20 risk of a prostate cancer death in men who were told they were ‘all clear’ on their 
first biopsy.  A rate that is nearly twice as high as the average lifetime risk of a 
prostate cancer death for the average male.   If we take the most recent data from 
ProtecT we have the rather difficult dilemma of telling men who test negative (by 
TRUS biopsy) that they are at least at five-time greater risk of dying of prostate 
cancer than the men with a confirmed diagnosis of prostate cancer who were 
followed up for longer.    
 
How could this be possible?  Well, clinical studies, by their very nature are more 
restrictive in terms of inclusion criteria than registries that are specifically designed 
to include all cases.  The SPCG-4 and PIVOT studies were relatively unrestrictive with 
regard to PSA (≤50ug/L) but did require men to be free of metastases as determined 
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by bone scan. ProtecT excluded men with a PSA of 20ug/L or more, so all studies 
included men with a PSA of up to 20ug/L.  When the analysis within the Danish 
registry study was restricted to men with a negative first-time biopsy that was 
associated with a PSA of less than 20ug/L the risk of dying of prostate cancer was 
preserved albeit at a slightly lower rate.   
 
Could these data from the Denmark registry be giving us some insight into our 
diagnostic efficiency?  The results from the PROMIS trial suggests that this might, 
indeed, be the case as more than half the clinically significant tumours were missed 
by biopsy.  The Danish study suggests that these men remain at risk over a fairly 
short period of follow-up.  Perhaps slightly more worrying is that the very men who 
test negative – despite harbouring significant prostate  - would not make it into any 
of our prostate cancer clinical trials in view of their ‘benign’ pathology.  Their 
prostate cancer-related deaths would occur outside the trials and registries and, as a 
consequence, would not be reported on.  The result is a systematic under-reporting 
of prostate cancer related deaths in our evidence base.  This might mean that the 
very things that are contingent of the quality of our evidence - risk calculators, 
shared decision making programs, tissue archives and our policy positions might 
carry this bias and, as a result, have got it all terribly wrong.   
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